2 results match your criteria: "241808National Institute for Health Development[Affiliation]"
Quality Assessment of Cervical Cytology Practices in Estonia From 2007 to 2018.
Cancer Control
December 2022
Department of Epidemiology and Biostatistics, 241808National Institute for Health Development, Tallinn, Estonia.
Background: Cervical cancer incidence and mortality in Estonia are among the highest in Europe, although the overall coverage with cervical cytology is high. This indicates potential issues with the quality of collection and/or laboratory evaluation of cervical cytology.
Objectives: The aim of the retrospective observational study was to assess the quality of cervical cytology specimen collection, evaluation, and reporting using laboratory reports in Estonia.
Human papillomavirus self-sampling for long-term non-attenders in cervical cancer screening: A randomised feasibility study in Estonia.
J Med Screen
March 2022
Department of Epidemiology and Biostatistics, 241808National Institute for Health Development, Tallinn, Estonia.
Article Synopsis
- - Organised cervical cancer screening in Estonia began in 2006, but participation remains low, so a study was conducted in 2020 to test the feasibility and acceptance of HPV self-sampling among women who had not attended screening.
- - A randomised intervention study involved 12,000 women born between 1958-1983, with varying methods of receiving self-sampling kits; the results showed a 16% overall participation rate, significantly higher in the opt-out group compared to the opt-in groups.
- - Findings indicated that self-sampling was well-received, with 98% of participants finding it easy to use and 88% expressing preference for it in future screenings, highlighting its potential to increase cervical